Skip to main
  1. Stocks
  2. Taysha Gene Therapies
  3. Forecast
TSHA

TSHA Stock Forecast & Price Target

TSHA Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Taysha Gene Therapies is viewed positively because TSHA-102 is showing unusually strong early efficacy in Rett syndrome, with an 83% response rate at six months and 100% at 12 months across 12 initial patients, plus 31 developmental milestones and 310 total functional gains. The data also look durable and differentiated, with broad improvements in communication, sleep, seizures, and motor skills, while safety remains clean across 29 treated patients with no treatment-related SAEs or DLTs. Fundamentally, the company benefits from a validated AAV9 platform and a pivotal trial that is fully overenrolled at 17 patients, supporting a favorable setup ahead of pivotal data in 1H27.

Bears say

Taysha Gene Therapies is viewed negatively because its lead CNS gene therapy assets remain exposed to substantial clinical failure risk, including the possibility that TSHA-102 does not show enough efficacy or a tolerable safety profile, with AAV programs also facing known concerns such as severe immunological responses and DRG toxicity. Regulatory uncertainty adds another layer of risk, since none of its drugs are approved by the FDA or EMA and intrathecal gene therapy may draw increased scrutiny, while commercialization would require building its own sales force and market presence. Financially, the company is likely to need additional equity financing to advance development, which raises dilution risk, and it faces a crowded Rett syndrome landscape with approved Daybue in March 2023, Anavex data, and Neurogene’s Phase I program.

TSHA has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.

TSHA Analyst Forecast & Price Prediction

Get the latest TSHA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TSHA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Taysha Gene Therapies (TSHA) Forecast

Analysts have given TSHA a Strong Buy based on their latest research and market trends.

According to 9 analysts, TSHA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Taysha Gene Therapies (TSHA)


TSHA Analyst Forecast & Price Prediction

Get the latest TSHA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TSHA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TSHA stock data and trends